IP Library › Granted Patent US 12,285,419
Granted Patent B2
US 12,285,419 · App. 18/046,416 · Granted Apr 29, 2025

Bupivacaine multivesicular liposome formulations and uses thereof

Inventors: Louie D. Garcia (San Diego, CA); Soroush M. Ardekani (San Diego, CA); Paige N. Davis (San Diego, CA); Stephanie M. Kurz (San Diego, CA); Damon A. Leon (San Diego, CA); Kathleen D. A. Los (San Diego, CA); John J. Grigsby, Jr. (San Diego, CA); Eran Levy (San Diego, CA); Alisha R. Simonian (San Diego, CA)
Assignee: Pacira Pharmaceuticals, Inc.
A61K31/445A61K9/127A61K47/14A61K47/28
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,285,419
App. No.
18/046,416
Granted
Apr 29, 2025
Kind
B2
Abstract

Some embodiments of the present application are related to multivesicular liposome formulations comprising high concentration of bupivacaine for the purpose of preventing, treating or ameliorating pain, for example, post-surgical pain for an extended period of time. Processes of making and administering bupivacaine encapsulated multivesicular liposome formulations (BUP-MVLs) and their uses as medicaments are also provided.

Claims (55)

1. A composition of bupivacaine encapsulated multivesicular liposomes (MVLs), comprising:

bupivacaine residing inside a plurality of internal aqueous chambers of the MVLs separated by lipid membranes, wherein the lipid membranes comprise DPPG or a salt thereof, DEPC, cholesterol, and a triglyceride selected from the group consisting of triolein, tricaprylin, and combinations thereof; and

an aqueous medium in which the bupivacaine encapsulated MVLs are suspended, wherein the aqueous medium comprises at least one buffering agent in a concentration from about 1 mM to about 50 mM, and wherein the osmolality of the aqueous medium is from about 320 mOsm/kg to about 360 mOsm/kg;

wherein the bupivacaine concentration in the composition is from about 18 mg/mL to about 40 mg/mL, and

wherein the plurality of internal aqueous chambers of the MVLs comprises one or more pH modifying agents, and has a pH from about 3.0 to about 6.6.

2. The composition of claim 1 , wherein the bupivacaine concentration in the composition is about 20 mg/mL.

3. The composition of claim 1 , wherein the composition comprises less than about 2% by weight of unencapsulated bupivacaine.

4. The composition of claim 1 , wherein the lipid membrane comprises DPPG, DEPC, cholesterol, tricaprylin, and triolein.

5. The composition of claim 1 , wherein the one or more pH modifying agents is selected from the group consisting of organic acids, organic bases, inorganic acids, and inorganic bases, and combinations thereof.

6. The composition of claim 5 , wherein the one or more pH modifying agents comprises phosphoric acid.

7. The composition of claim 1 , wherein the plurality of internal aqueous chambers of the MVLs has a pH from about 3.5 to about 6.6.

8. The composition of claim 1 , wherein the percent packed particle volume (% PPV) of the bupivacaine encapsulated multivesicular liposomes in the composition is about 35% to 80%.

9. The composition of claim 1 , wherein the at least one buffering agent comprises sodium phosphate.

10. The composition of claim 9 , wherein the concentration of sodium phosphate in the composition is from about 5 mM to about 20 mM.

11. The composition of claim 1 , wherein the pH of the aqueous medium is from about 6.5 to about 7.5.

12. The composition of claim 3 , wherein the increase of unencapsulated bupivacaine in the composition is less than about 5% by weight after the composition is stored at 5° C. for six months.

13. The composition of claim 1 , wherein the bupivacaine is in the form of bupivacaine phosphate.

14. A method of treating or ameliorating pain in a subject in need thereof, comprising administering a composition of claim 1 to the subject.

15. The method of claim 14 , wherein the administration is selected from the group consisting of infiltration, subcutaneous injection, tissue injection, intramuscular injection, spinal injection, intraocular injection, epidural injection, subarachnoid injection, sacroiliac joints injection, intrathecal injection, caudal injection, intraotic injection, and perineural injection, and combinations thereof.

16. The method of claim 14 , wherein the administration is via local infiltration to a surgical site.

17. The method of claim 14 , wherein the administration is via nerve block.

18. The method of claim 17 , wherein the administration is via interscalene brachial plexus nerve block, femoral nerve block, sciatic nerve block, or ganglion block.

19. The method of claim 14 , wherein the pain is post-surgical pain or chronic pain.

20. The method of claim 19 , wherein the chronic pain comprises myofascial pain syndromes, complex regional pain syndromes, or radicular back pain.

21. The method of claim 14 , wherein the Tmax of bupivacaine is from about 6 hours to about 96 hours.

22. The method of claim 14 , wherein the percent AUC (0-24 hours) of bupivacaine is from about 4% to about 25%, from about 6% to about 20%, or from about 8% to about 15%.

23. The method of claim 14 , wherein the total percent AUC is above 90% from 192 hours to about 216 hours post administration.

24. The method of claim 14 , wherein the Cmax of bupivacaine is from about 40 ng/ml to about 100 ng/ml.

25. The method of claim 14 , wherein the administration provides a sustained release of bupivacaine for about 5 to 15 days.

26. A process for preparing bupivacaine encapsulated multivesicular liposomes (MVLs), comprising:

mixing a first aqueous solution comprising one or more pH modifying agents with a lipid solution comprising at least one organic solvent, DPPG or a salt thereof, DEPC, cholesterol, and a triglyceride selected from the group consisting of triolein, tricaprylin, and combinations thereof to form a first water-in-oil emulsion, wherein at least one of the first aqueous solution and the lipid solution comprises bupivacaine;

combining the first water-in-oil emulsion with a second aqueous solution to form a second emulsion; and

substantially removing the organic solvent from the second emulsion to form a first aqueous suspension of bupivacaine encapsulated MVLs; and

exchanging the aqueous supernatant of the first aqueous suspension with a third aqueous solution one or more times to provide a final aqueous suspension of bupivacaine encapsulated MVLs, wherein the bupivacaine concentration in the final aqueous suspension is from about 18 mg/mL to about 40 mg/mL, and wherein the final aqueous suspension comprises at least one buffering agent in a concentration from about 1 mM to about 50 mM; and wherein the osmolality of the final aqueous suspension is from about 320 mOsm/kg to about 360 mOsm/kg.

27. The process of claim 26 , wherein the bupivacaine concentration in the final aqueous suspension is about 20 mg/mL.

28. The process of claim 26 , wherein the one or more pH modifying agents in the first aqueous solution comprises phosphoric acid.

29. The process of claim 28 , wherein the molar ratio of bupivacaine to phosphoric acid in the first aqueous solution is from about 1:1.2 to about 1:2.

30. The process of claim 26 , wherein the second aqueous solution comprises lysine and dextrose, and the second aqueous solution has the osmolality from about 210 mOsm/kg to about 285 mOsm/kg.

31. The process of claim 26 , wherein the lipid solution comprises DPPG or a salt thereof, DEPC, cholesterol, tricaprylin, and triolein.

32. The process of claim 31 , wherein the mass ratio of tricaprylin to triolein is from about 3:1 to about 25:1.

33. The composition of claim 4 , wherein the mass ratio of tricaprylin to triolein is from about 3:1 to about 25:1.

34. A composition of bupivacaine encapsulated multivesicular liposomes (MVLs), comprising:

bupivacaine residing inside a plurality of internal aqueous chambers of the MVLs separated by lipid membranes, wherein the lipid membranes comprise DPPG or a salt thereof, DEPC, cholesterol, tricaprylin and triolein; and

an aqueous medium in which the bupivacaine encapsulated MVLs are suspended, wherein the aqueous medium comprises one or more buffering agents in a concentration from about 5 mM to about 20 mM, wherein the osmolality of the aqueous medium is from about 320 mOsm/kg to about 360 mOsm/kg, and the pH of the aqueous medium is from about 6.5 to about 7.5;

wherein the bupivacaine concentration in the composition is about 20 mg/mL;

wherein the plurality of internal aqueous chambers of the MVLs comprises phosphoric acid as a pH modifying agent, and has a pH from about 3.5 to about 6.6; and

wherein the mass ratio of tricaprylin to triolein in the composition is about 5:1 to about 15:1.

35. The composition of claim 34 , wherein the aqueous medium comprises about 10 mM sodium phosphate.

36. The composition of claim 35 , wherein the osmolality of the aqueous medium is about 330 mOsm/kg.

37. The composition of claim 34 , wherein the concentration of DEPC in the composition is from about 8 mg/mL to 12 mg/ml;

the concentration of DPPG or a salt thereof in the composition is from about 0.7 mg/mL to about 1.5 mg/ml;

the concentration of cholesterol in the composition is from about 4 mg/mL to about 7 mg/mL;

the concentration of tricaprylin in the composition is from about 2 mg/mL to about 5 mg/mL; and

the concentration of triolein in the composition is about 0.3 mg/mL to about 1.0 mg/mL.

38. A method of treating or ameliorating pain in a subject in need thereof, comprising administering a composition of claim 34 to the subject by a single injection, and wherein the administration provides a sustained release of bupivacaine for 5 to 15 days.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Dec 5, 2025
From: JPMORGAN CHASE BANK, N.A.
To: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; PACIRA THERAPEUTICS, INC. (F/K/A FLEXION THERAPEUTICS, INC.)
Reel/Frame 073779/0532 →
SECURITY INTEREST Recorded Jul 4, 2025
From: PACIRA PHARMACEUTICALS, INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 071814/0792 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Mar 31, 2023
From: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; PACIRA THERAPEUTICS, INC. (F/K/A FLEXION THERAPEUTICS, INC.)
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 063214/0108 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2023
From: GARCIA, LOUIE D.; ARDEKANI, SOROUSH M.; DAVIS, PAIGE N.; KURZ, STEPHANIE M.; LEON, DAMON A.; LOS, KATHLEEN D.A.; GRIGSBY, JOHN J., JR.; LEVY, ERAN; SIMONIAN, ALISHA R.
To: PACIRA PHARMACEUTICALS, INC.
Reel/Frame 062496/0264 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2022
From: GARCIA, LOUIE D.; ARDEKANI, SOROUSH M.; DAVIS, PAIGE N.; KURZ, STEPHANIE M.; LEON, DAMON A.; LOS, KATHLEEN D.A.; GRIGSBY, JOHN J., JR.; LEVY, ERAN; SIMONIAN, ALISHA R.
To: PACIRA PHARMACEUTICALS, INC.
Reel/Frame 061642/0784 →
Continuity (2)
Provisional Application 63255690 · Oct 14, 2021
Related Publication 20230133849A1 · May 4, 2023
References Cited (327)
US 3684251A · Bowling · 1972 [cited by applicant]
US 3946994A · Mertz et al. · 1976 [cited by applicant]
US 4026817A · Ciuti et al. · 1977 [cited by applicant]
US 4078052A · Papahadjopoulos · 1978 [cited by applicant]
US 4089801A · Schneider · 1978 [cited by applicant]
US 4113765A · Richardson et al. · 1978 [cited by applicant]
US 4145410A · Sears · 1979 [cited by applicant]
US 4224179A · Schneider · 1980 [cited by applicant]
US 4235587A · Miles · 1980 [cited by applicant]
US 4235871A · Papahadjopoulos et al. · 1980 [cited by applicant]
US 4310506A · Baldeschwieler et al. · 1982 [cited by applicant]
US 4394372A · Taylor · 1983 [cited by applicant]
US 4420398A · Castino · 1983 [cited by applicant]
US 4454083A · Brown et al. · 1984 [cited by applicant]
US 4478824A · Franco et al. · 1984 [cited by applicant]
US 4522803A · Lenk et al. · 1985 [cited by applicant]
US 4588578A · Fountain et al. · 1986 [cited by applicant]
US 4590030A · Gillner et al. · 1986 [cited by applicant]
US 4599227A · Dees et al. · 1986 [cited by applicant]
US 4599342A · LaHann · 1986 [cited by applicant]
US 4610868A · Fountain et al. · 1986 [cited by applicant]
US 4622219A · Haynes · 1986 [cited by applicant]
US 4644056A · Kothe et al. · 1987 [cited by applicant]
US 4652441A · Okada et al. · 1987 [cited by applicant]
US 4668580A · Dahm et al. · 1987 [cited by applicant]
US 4711782A · Okada et al. · 1987 [cited by applicant]
US 4725442A · Haynes · 1988 [cited by applicant]
US 4744989A · Payne et al. · 1988 [cited by applicant]
US 4752425A · Martin et al. · 1988 [cited by applicant]
US 4761255A · Dahm et al. · 1988 [cited by applicant]
US 4761288A · Mezei · 1988 [cited by applicant]
US 4769250A · Forssen · 1988 [cited by applicant]
US 4776991A · Farmer et al. · 1988 [cited by applicant]
US 4781831A · Goldsmith · 1988 [cited by applicant]
US 4781871A · West, III et al. · 1988 [cited by applicant]
US 4788001A · Narula · 1988 [cited by applicant]
US 4844620A · Lissant et al. · 1989 [cited by applicant]
US 4844904A · Hamaguchi et al. · 1989 [cited by applicant]
US 4861597A · Kida et al. · 1989 [cited by applicant]
US 4877561A · Iga et al. · 1989 [cited by applicant]
US 4877619A · Richer · 1989 [cited by applicant]
US 4908463A · Bottelberghe · 1990 [cited by applicant]
US 4920016A · Allen et al. · 1990 [cited by applicant]
US 4921644A · Lau et al. · 1990 [cited by applicant]
US 4921853A · LeBlanc · 1990 [cited by applicant]
US 4937078A · Mezei et al. · 1990 [cited by applicant]
US 4946683A · Forssen · 1990 [cited by applicant]
US 4956290A · Harrison et al. · 1990 [cited by applicant]
US 5000959A · Iga et al. · 1991 [cited by applicant]
US 5004611A · Leigh · 1991 [cited by applicant]
US 5013556A · Woodle et al. · 1991 [cited by applicant]
US 5019394A · Hamaguchi et al. · 1991 [cited by applicant]
US 5021200A · Vanlerberghe et al. · 1991 [cited by applicant]
US 5049392A · Weiner et al. · 1991 [cited by applicant]
US 5069936A · Yen · 1991 [cited by applicant]
US 5077056A · Bally et al. · 1991 [cited by applicant]
US 5091187A · Haynes · 1992 [cited by applicant]
US 5094854A · Ogawa et al. · 1992 [cited by applicant]
US 5100591A · Leclef et al. · 1992 [cited by applicant]
US 5141674A · Leigh · 1992 [cited by applicant]
US 5147134A · Bradley et al. · 1992 [cited by applicant]
US 5169637A · Lenk et al. · 1992 [cited by applicant]
US 5186941A · Callahan et al. · 1993 [cited by applicant]
US 5192549A · Barenolz et al. · 1993 [cited by applicant]
US 5204112A · Hope et al. · 1993 [cited by applicant]
US 5211955A · Legros et al. · 1993 [cited by applicant]
US 5225212A · Martin et al. · 1993 [cited by applicant]
US 5227165A · Domb et al. · 1993 [cited by applicant]
US 5227170A · Sullivan · 1993 [cited by applicant]
US 5244678A · Legros et al. · 1993 [cited by applicant]
US 5246707A · Haynes · 1993 [cited by applicant]
US 5261903A · Dhaliwal et al. · 1993 [cited by applicant]
US 5292701A · Glemza et al. · 1994 [cited by applicant]
US 5321012A · Mayer et al. · 1994 [cited by applicant]
US 5334381A · Unger · 1994 [cited by applicant]
US 5334391A · Clark et al. · 1994 [cited by applicant]
US 5364632A · Benita et al. · 1994 [cited by applicant]
US 5387387A · James et al. · 1995 [cited by applicant]
US 5393530A · Schneider et al. · 1995 [cited by applicant]
US 5407660A · Bosworth et al. · 1995 [cited by applicant]
US 5415867A · Minchey et al. · 1995 [cited by applicant]
US 5422120A · Kim · 1995 [cited by applicant]
US 5451408A · Mezei et al. · 1995 [cited by applicant]
US 5455044A · Kim et al. · 1995 [cited by applicant]
US RE35192E · Reese · 1996 [cited by applicant]
US 5533526A · Goldberg · 1996 [cited by applicant]
US 5543158A · Gref et al. · 1996 [cited by applicant]
US 5576017A · Kim · 1996 [cited by applicant]
US 5576018A · Kim et al. · 1996 [cited by applicant]
US 5589189A · Moynihan · 1996 [cited by applicant]
US 5635205A · Nyqvist et al. · 1997 [cited by applicant]
US 5658898A · Weder et al. · 1997 [cited by applicant]
US 5662931A · Munechika et al. · 1997 [cited by applicant]
US 5681464A · Larsson · 1997 [cited by applicant]
US 5700482A · Frederiksen et al. · 1997 [cited by applicant]
US 5708011A · Bardsley et al. · 1998 [cited by applicant]
US 5723147A · Kim et al. · 1998 [cited by applicant]
US 5766627A · Sankaram et al. · 1998 [cited by applicant]
US 5770222A · Unger et al. · 1998 [cited by applicant]
US 5776486A · Castor et al. · 1998 [cited by applicant]
US 5776915A · Peterson et al. · 1998 [cited by applicant]
US 5807573A · Ljusberg-Wahren et al. · 1998 [cited by applicant]
US 5814335A · Webb et al. · 1998 [cited by applicant]
US 5827533A · Needham · 1998 [cited by applicant]
US 5837282A · Fenske et al. · 1998 [cited by applicant]
US 5849763A · Bardsley et al. · 1998 [cited by applicant]
US 5853755A · Foldvari · 1998 [cited by applicant]
US 5865184A · Takiguchi · 1999 [cited by applicant]
US 5879672A · Davis et al. · 1999 [cited by applicant]
US 5882679A · Needham · 1999 [cited by applicant]
US 5885260A · Mehl, Sr. et al. · 1999 [cited by applicant]
US 5891467A · Willis · 1999 [cited by applicant]
US 5891842A · Kream · 1999 [cited by applicant]
US 5895661A · Tournier et al. · 1999 [cited by applicant]
US 5910502A · Gennery · 1999 [cited by applicant]
US 5912271A · Brodin et al. · 1999 [cited by applicant]
US 5919804A · Gennery · 1999 [cited by applicant]
US 5922340A · Berde et al. · 1999 [cited by applicant]
US 5942253A · Gombotz et al. · 1999 [cited by applicant]
US 5945126A · Thanoo et al. · 1999 [cited by applicant]
US 5945435A · Evetts · 1999 [cited by applicant]
US 5947689A · Schick · 1999 [cited by applicant]
US 5948441A · Lenk et al. · 1999 [cited by applicant]
US 5955087A · Whittle et al. · 1999 [cited by applicant]
US 5955479A · Bardsley et al. · 1999 [cited by applicant]
US 5962016A · Willis · 1999 [cited by applicant]
US 5962532A · Campbell et al. · 1999 [cited by applicant]
US 5977326A · Scheinmann et al. · 1999 [cited by applicant]
US 5980927A · Nelson et al. · 1999 [cited by applicant]
US 5980937A · Tournier et al. · 1999 [cited by applicant]
US 5997899A · Ye et al. · 1999 [cited by applicant]
US 6007838A · Alving et al. · 1999 [cited by applicant]
US 6033708A · Kwasiborski et al. · 2000 [cited by applicant]
US 6045824A · Kim et al. · 2000 [cited by applicant]
US 6046187A · Berde et al. · 2000 [cited by applicant]
US 6048545A · Keller et al. · 2000 [cited by applicant]
US 6066331A · Barenholz et al. · 2000 [cited by applicant]
US 6069155A · Mather et al. · 2000 [cited by applicant]
US 6071534A · Kim et al. · 2000 [cited by applicant]
US 6103741A · Bardsley et al. · 2000 [cited by applicant]
US 6106858A · Ye et al. · 2000 [cited by applicant]
US 6120797A · Meers et al. · 2000 [cited by applicant]
US 6132766A · Sankaram et al. · 2000 [cited by applicant]
US 6149937A · Camu et al. · 2000 [cited by applicant]
US 6171613B1 · Ye et al. · 2001 [cited by applicant]
US 6193998B1 · Ye et al. · 2001 [cited by applicant]
US 6217899B1 · Benameur et al. · 2001 [cited by applicant]
US 6221385B1 · Camu et al. · 2001 [cited by applicant]
US 6221401B1 · Zasadzinski et al. · 2001 [cited by applicant]
US 6238702B1 · Berde et al. · 2001 [cited by applicant]
US 6241999B1 · Ye et al. · 2001 [cited by applicant]
US 6264988B1 · Yen · 2001 [cited by applicant]
US 6270802B1 · Thanoo et al. · 2001 [cited by applicant]
US 6287587B2 · Shigeyuki et al. · 2001 [cited by applicant]
US 6306432B1 · Shirley et al. · 2001 [cited by applicant]
US 6355267B1 · Collins · 2002 [cited by applicant]
US 6399094B1 · Brandl et al. · 2002 [cited by applicant]
US 6417201B1 · Bardsley et al. · 2002 [cited by applicant]
US 8182835B2 · Kim et al. · 2012 [cited by applicant]
US 8834921B2 · Kim et al. · 2014 [cited by applicant]
US 9192575B2 · Kim et al. · 2015 [cited by applicant]
US 9205052B2 · Kim et al. · 2015 [cited by applicant]
US 9585838B2 · Hartounian et al. · 2017 [cited by applicant]
US 9730892B2 · Schutt et al. · 2017 [cited by applicant]
US 10398648B2 · Schutt · 2019 [cited by applicant]
US 10449152B2 · Ohri · 2019 [cited by examiner]
US 10842745B2 · Barenholz et al. · 2020 [cited by applicant]
US 11033495B1 · Hall et al. · 2021 [cited by applicant]
US 11185506B1 · Hall et al. · 2021 [cited by applicant]
US 11179336B1 · Hall et al. · 2021 [cited by applicant]
US 11278494B1 · Hall et al. · 2022 [cited by applicant]
US 11304904B1 · Hall et al. · 2022 [cited by applicant]
US 11311486B1 · Hall et al. · 2022 [cited by applicant]
US 11357727B1 · Hall et al. · 2022 [cited by applicant]
US 11426348B2 · Hall et al. · 2022 [cited by applicant]
US 11452691B1 · Hall et al. · 2022 [cited by applicant]
US 11925706B2 · Hall et al. · 2024 [cited by applicant]
US 20020039596A1 · Hartounian et al. · 2002 [cited by applicant]
US 20020041895A1 · Gregoriadis et al. · 2002 [cited by applicant]
US 20030201230A1 · Kopf · 2003 [cited by applicant]
US 20040247659A1 · Eibl · 2004 [cited by applicant]
US 20110244029A1 · Barenholz · 2011 [cited by examiner]
US 20110250264A1 · Schutt et al. · 2011 [cited by applicant]
US 20130183375A1 · Schutt · 2013 [cited by applicant]
US 20130189350A1 · Garcia et al. · 2013 [cited by applicant]
US 20130251786A1 · Li · 2013 [cited by applicant]
US 20140004173A1 · Hartounian et al. · 2014 [cited by applicant]
US 20140319045A1 · Shevitz · 2014 [cited by applicant]
US 20150158907A1 · Zhou · 2015 [cited by applicant]
US 20180161275A1 · Los et al. · 2018 [cited by applicant]
US 20190169559A1 · Coffman · 2019 [cited by applicant]
US 20190314281A1 · Ma et al. · 2019 [cited by applicant]
US 20220233447A1 · Hall et al. · 2022 [cited by applicant]
US 20220233448A1 · Hall et al. · 2022 [cited by applicant]
US 20220304932A1 · Hall et al. · 2022 [cited by applicant]
US 20230248648A1 · Hall et al. · 2023 [cited by applicant]
US 20230301916A1 · Hall et al. · 2023 [cited by applicant]
CA 2078666 · 1991 [cited by applicant]
CA 1323568 · 1993 [cited by applicant]
CA 2176712 · 1995 [cited by applicant]
CA 1337273 · 1995 [cited by applicant]
CA 2199004 · 2000 [cited by applicant]
CN 110179752A · 2019 [cited by applicant]
CN 108078929B · 2021 [cited by applicant]
EP 0126580 · 1984 [cited by applicant]
EP 0208450 · 1987 [cited by applicant]
EP 0506639 · 1992 [cited by applicant]
EP 0280503 · 1993 [cited by applicant]
EP 0752245 · 1997 [cited by applicant]
EP 3572070 · 2019 [cited by applicant]
GB 2050287 · 1981 [cited by applicant]
WO WO8503011 · 1985 [cited by applicant]
WO WO8900846 · 1989 [cited by applicant]
WO WO8904656 · 1989 [cited by applicant]
WO WO9114445 · 1991 [cited by applicant]
WO WO9300888 · 1993 [cited by applicant]
WO WO9408565 · 1994 [cited by applicant]
WO WO9408626 · 1994 [cited by applicant]
WO WO9422430 · 1994 [cited by applicant]
WO WO9423697 · 1994 [cited by applicant]
WO WO9426250 · 1994 [cited by applicant]
WO WO9426253 · 1994 [cited by applicant]
WO WO9427581 · 1994 [cited by applicant]
WO WO9501164 · 1995 [cited by applicant]
WO WO9513796 · 1995 [cited by applicant]
WO WO9608235 · 1996 [cited by applicant]
WO WO9614057 · 1996 [cited by applicant]
WO WO9702022 · 1997 [cited by applicant]
WO WO9703652 · 1997 [cited by applicant]
WO WO9735561 · 1997 [cited by applicant]
WO WO98014171 · 1998 [cited by applicant]
WO WO98033483 · 1998 [cited by applicant]
WO 9912523 · 1999 [cited by examiner]
WO 9913865 · 1999 [cited by examiner]
WO WO12109387 · 2012 [cited by applicant]
WO WO2111299 · 2021 [cited by applicant]
“Guidance for Industry: Guideline on Sterile Drug Products Produced by Aseptic Processing,” Jun. 1987, Reprinted Jun. 1991, pp. 1-43, Center for Drug Evaluation and Research et al. [cited by applicant]
“Local Anesthetics,” New Pharmacology, Revised 3.sup.rd ed., pp. 261-266, Tanaka et al. eds. Nankoudou Corp., Aug. 1, 1997. [cited by applicant]
Sep. 30, 2021 Bupivacaine liposome injectable suspension ANDA No. 214348, Paragraph IV Notice Letter Invalidity contentions for U.S. Pat. No. 11,033,495. [cited by applicant]
Dec. 28, 2021 Redacted Bupivacaine liposome injectable suspension ANDA No. 214348, Paragraph IV Notice Letter Invalidity contentions for U.S. Pat. No. 11,179,336. [cited by applicant]
Andrews et al., “Boundary Layer Solution for a Bubble Rising Through a Liquid Containing Surface-Active Contaminants,” Ind. Eng. Chem. Res., 1995, 34(4):1371-1382. [cited by applicant]
Arroyo et al., “Use of intermittent jets to enhance flux in crossflow filtration,” J. Membrane Sci., 1993, 80:117-129. [cited by applicant]
Assil et al., “Liposome Suppression of Proliferative Vitreoretinopathy: Rabbit Model Using Antimetabolite Encapsulated Liposomes,” Invest. Ophthalmol. Vis. Sci., 32(11):2891-2897, 1991. [cited by applicant]
Assil et al., “Multivesicular Liposomes: Sustained Release of the Antimetabolite Cytarabine in the Eye,” Arch Ophthalmol., 1987, 105(3):400-403. [cited by applicant]
Assil et al., “Tobramycin Liposomes: Single Subconjunctival Therapy of Pseudomonal Keratitis,” Invest. Ophthalmol. Vis. Sci., 32(13):3216-3220, 1991. [cited by applicant]
Bangham et al., “Diffusion of Univalent lons Across the Lamellae of Swollen Phospholipids,” J. Mol. Biol., 1965, 13:238-252. [cited by applicant]
Barbet et al., “Weak acid-induced release of liposome-encapsulated carboxyfluorescein,” Biochim. Biophys. Acta, 1984, 772:347-356. [cited by applicant]
Bhave, “Cross-Flow Filtration,” Fermentation and Biochemical Engineering Handbook: Principles, Process Design and Equipment, 2.sup.nd edition, (Vogel et al. Eds., 1997), Noyes Publications, Westwood, New Jersey, pp. 271… [cited by applicant]
Bonetti et al., “An extended-release formulation of methotrexate for subcutaneous administration,” Cancer Chemother. Pharmacol., 33:303-306, 1994. [cited by applicant]
Boogaerts et al. “Biodistribution of liposome-associated bupivacaine after extradural administration to rabbits,” Br. J. Anaesth, 1995, 75:319-325. [cited by applicant]
Boogaerts et al. “Epidural Administration of Liposome-Associated Bupivacaine for the Management of Postsurgical Pain: A First Study,” J. Clin. Anesth, 1994, 6:315-320. [cited by applicant]
Boogaerts et al. “Motor Blockade and Absence of Local Nerve Toxicity Induced by Liposomal Bupivacaine Injected into the Axillary Plexus of Rabbits,” Acta Anesth. Belg., 1995, 46:19-24. [cited by applicant]
Boogaerts et al. “Plasma concentrations of bupivacaine after brachial plexus administration of liposome-associated and plain solutions to rabbits,” Can. J. Anaesth, 1993, 40:1201-1204. [cited by applicant]
Boogaerts et al. “Toxicity of Bupivacaine Encapsulated into Liposomes and Injected Intravenously: Comparison with Plan Solutions,” Anesth. Analg., 1993, 76:553-555. [cited by applicant]
Chamberlain et al., “Treatment of Leptomeningeal Metastasis With Intraventricular Administration of Depot Cytarabine (DTC 101): A Phase | Study,” Arch. Neurol., 50:261-264, 1993. [cited by applicant]
Chatelut et al., “A slow-release methotrexate formulation for intrathecal chemotherapy,” Cancer Chemother. Pharmacol., 32:179-182, 1993. [cited by applicant]
Chattopadhyay et al., “The Protective Effect of Specific Medium Additives with Respect to Bubble Rupture,” Biotechnol. Bioeng., 1995, 45(6):473-480. [cited by applicant]
Chemical Comprehensive Dictionary, compact 2.sup.rd ed., Kyoritsushuppan Corp., edited by the Editorial Committee of the Chemical Comprehensive Dictionary, Aug. 25, 1963, pp. 725-726. [cited by applicant]
Cherry et al., “Cell Death in the Thin Films of Bursting Bubbles,” Biotechnol. Prog., 1992, 8(1):11-18. [cited by applicant]
Cullis et al., “Structural Properties and Functional Roles of Phospholipids in Biological Membranes,” Phospholipids and Cellular Regulation, pp. 1-59, vol. 1, J.F. Kuo ed., CRC Press, 1985, Boca Raton, FL. [cited by applicant]
Davidson et al., 2010, High-dose bupivacaine remotely loaded into multivesicular liposomes demonstrates slow drug release without systemic toxic plasma concentrations after subcutaneous administration in humans, Anethes… [cited by applicant]
De Gier, J et al., Lipid Composition and Permeability of Liposomes, Biochim. Biophys. Acta 150:666-675 (1968). [cited by applicant]
Edwards et al., “Large Porous Particles for Pulmonary Drug Delivery,” Science, 1997, 276: 1868-1871. [cited by applicant]
Frucht-Perry et al., “Fibrin-Enmeshed Tobramycin Liposomes: Single Application Topical Therapy of Pseudomonas Keratitis,” Cornea, 1992, 11(5):393-397. [cited by applicant]
Genovesi, “Several uses for tangential-flow filtration in the pharmaceutical industry,” J. Parenter. Sci. Technol. (1983), 37(3):81-86. [cited by applicant]
Grit et al., Apr. 1993, Hydrolysis of saturated soybean phosphatidylcholine in aqueous liposome dispersions, Journal of Pharmaceutical Sciences, 82(4):362-366. [cited by applicant]
Gruner et al., “Novel Multilayered Lipid Vesicles: Comparison of Physical Characteristics of Multilamellar Liposomes and Stable Plurilamellar Vesicles,” Biochemistry, 1985, 24(12):2833-2842. [cited by applicant]
Holdich et al., “The variation of crossflow filtration rate with wall shear stress and the effect of deposit thickness,” Chemical Engineering Research and Design (Trans IChem), 1995, 73(part A):20-26. [cited by applicant]
Huang, “Studies on Phosphatidylcholine Vesicles. Formation and Physical Characteristics,” Biochemistry, 1969, 8(1):344-352. [cited by applicant]
Huang, et al., “Determination of phospholipid and fatty glyceride in liposome by RP-HPLC with capacitively coupled contactless conductivity detector,” Analytical Methods, 2018, 10, 4978-4984. [cited by applicant]
Ishii, “Production and size control of large unilamellar liposomes by emulsification,” Liposome Technology 2.sup.nd Edition, pp. 111-121, vol. 1, Gregory Gregoriadis ed., CRC Press, 1993, Boca Raton, FL. [cited by applicant]
Jaffrin et al., “Energy saving pulsatile mode cross flow filtration,” J. Membrane Sci., 1994, 86:281-290. [cited by applicant]
Johnson et al., “New nozzle improves FCC feed atomization, unit yield patterns,” Oil and Gas Journal, 1994, 92(3):80-86. [cited by applicant]
Joshi et al., “The safety of liposome bupivacaine following various routes of administration in animals” J. Pain. Res., 8, 781-789 (2015). [cited by applicant]
Kawashima et al., “Shear-Induced Phase Inversion and Size Control of Water/Oil/Water Emulsion Droplets with Porous Membrane,” J. Colloid Interface Sci., 1991, 145(2):512-523. [cited by applicant]
Kim “Liposomes as Carriers of Cancer Chemotherapy: Current status and Future Prospects,” Drugs, 46(4):618-638,1993. [cited by applicant]
Kim et al., “Direct Cerebrospinal Fluid Delivery of an Antiretroviral Agent Using Multivesicular Liposomes,” J. Infect. Dis., 1990, 162(3):750-752. [cited by applicant]
Kim et al., “Extended CSF Cytarabine Exposure Following Intrathecal Administration of DTC 101,” J. Olin. Oncol., 1993, 11(11):2186-2193. [cited by applicant]
Kim et al., “Extended-release formulation of morphine for subcutaneous administration,” Cancer Chemother. Pharmacol., 1993, 33(3):187-190. [cited by applicant]
Kim et al., “Modulation of the peritoneal clearance of liposomal cytosine arabinoside by blank liposomes,” Cancer Chemother. Pharmacol., 1987, 19(4):307-310. [cited by applicant]
Kim et al., “Multivesicular Liposomes Containing 1-beta-D-Arabinofuranosylcytosine for Slow-Release Intrathecal Therapy,” Cancer Res., 47(15):3935-3937, 1987. [cited by applicant]
Kim et al., “Multivesicular Liposomes Containing Cytarabine Entrapped in the Presence of Hydrochloric Acid for Intracavitary Chemotherapy,” Cancer Treat. Rep., 71(7-8):705-711, 1987. [cited by applicant]
Kim et al., “Multivesicular Liposomes Containing Cytarabine for Slow-Release Sc Administration,” Cancer Treat. Rep., 71(5):447-450, 1987. [cited by applicant]
Kim et al., “Preparation of cell-size unilamellar liposomes with high captured volume and defined size distribution,” Biochim. Biophys. Acta, 1981, 646:1-9. [cited by applicant]
Kim et al., “Preparation of multilamellar vesicles of defined size-distribution by solvent-spherule evaporation,” Biochim. Biophys. Acta, 1985, 812:793-801. [cited by applicant]
Kim et al., “Preparation of Multivesicular Liposomes,” Biochim. Biophys. Acta, 728(3):339-348, 1983. [cited by applicant]
Kim et al., “Prolongation of Drug Exposure in Cerebrospinal Fluid by Encapsulation into DepoFoam,” Cancer Res., 53(7):1596-1598, 1993. [cited by applicant]
Kim, T. et al., “Extended-release formulations of morphine for subcutaneous administration,” Cancer Chemother. Pharmacol., vol. 33, pp. 187-190 (1993). [cited by applicant]
Lafont et al. “Use of Liposome-Associated Bupivacaine for the Management of a Chronic Pain Syndrome,” Anesth. Analg., 1994, 79:818. [cited by applicant]
Lafont et al. “Use of Liposome-Associated Bupivacaine in a Cancer Pain Syndrome,” Anaesthesia, 1996, 51:578-579. [cited by applicant]
Legros et al. “Influence of Different Liposomal Formulations on the Pharmacokinetics of Encapsulated Bupivacaine,” [Abstract]. Anesthesiology, 1990, 73: A851. [cited by applicant]
Liposome Drug Products. Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation. Guidance for Industry, U.S. Department of Health and Human Services, Food and Drug … [cited by applicant]
Maa et al., “Liquid-liquid emulsification by rotor/stator homogenization,” J. Controlled Release, 1996, 38:219-228. [cited by applicant]
Maestre et al., “Contribution of Light Scattering to the Circular Dichroism of Deoxyribonucleic Acid Films, Deoxyribonucleic Acid-Polylysine Complexes, and Deoxyribonucleic Acid Particles in Ethanolic Buffers,” Biochemi… [cited by applicant]
Malinovsky et al., “Neurotoxilogical Assessment After Intracisternal Injection of Liposomal Bupivacaine in Rabbits,” Anesth. Analg., 1997, 85:1331-1336. [cited by applicant]
Mancini, “Mastering the mix: Why Leave Mixing to Chance? Get a Proper Mix and a Better Product Every Time,” Food Engineering, Mar. 1996, pp. 79-83. [cited by applicant]
Maranges et al., “Crossflow Filtration of [cited by applicant]
Mashimo et al. “Prolongation of Canine Epidural Anesthesia by Liposome Encapsulation of Lidocaine,” Anesth. Analg., 1992, 74:827-834. [cited by applicant]
Matsumoto et al., “An Attempt at Preparing Water-in-Oil-in-Water Multiple-Phase Emulsions,” J. Colloid Interface Sci., 1976, 57(2):353-361. [cited by applicant]
Meissner, D., et al., Application of High Frequency Backpulsing in Diafiltration of Multivesicular Liposomes, North American Membrane Society, Proceedings, 9.sup.th Annual Meeting, May 31-Jun. 4, 1997, Baltimore, MD, (1… [cited by applicant]
Meissner, D., et al., Application of Unsteady Flow Patterns in Permeate and Retentate for the Diafiltration of Multivesicular Lipid Based Particles, Annual AIChE Meeting, Nov. 16-21, 1997, Los Angeles, CA. Unpublished c… [cited by applicant]
Michaels et al., “Sparging and Agitation-Induced Injury of Cultured Animal Cells: Do Cell-to-Bubble Interactions in the Bulk Liquid Injure Cells?” Biotechnol. Bioeng., 1996, 51(4):399-409. [cited by applicant]
Mutsakis et al., “Advances in Static Mixing Technology,” Chem. Eng. Prog, Jul. 1986, pp. 42-48. [cited by applicant]
Narhi et al., “Role of Native Disulfide Bonds in the Structure and Activity of Insulin-like Growth Factor 1: Genetic Models of Protein-Folding Intermediates,” Biochemistry, 1993, 32(19):5214-5221. [cited by applicant]
Pacira Pharmaceuticals Inc., 2018, Exparel prescribing information, 28 pp. [cited by applicant]
Paul, “Reaction Systems for Bulk Pharmaceutical Production,” Chem. Ind., May 21, 1990, pp. 320-325. [cited by applicant]
Quirk et al., “Investigation of the parameters affecting the separation of bacterial enzymes from cell debris by tangential flow filtration,” Enzyme Microb. Technol. (1984), 6(5):201-206. [cited by applicant]
Radlett, “The Concentration of Mammalian Cells in a Tangential Flow Filtration Unit,” J. Appl. Chem. Biotechnol. (1972), 22:495-499. [cited by applicant]
Redkar et al., “Cross-Flow Microfiltration with High-Frequency Reverse Filtration,” AIChE Journal, 1995, 41(3):501-508. [cited by applicant]
Richard et al., 2011, The safety and tolerability evaluation of DepoFoam, bupivacaine (bupivacaine extended-relase liposome injection) administered by incision would infltration in rabbits and dogs, Expert Opinion on In… [cited by applicant]
Ripperger, et al., “Crossflow microfiltration—state of the art,” Separation and Purification Technology, 26 (2002), 19-31. [cited by applicant]
Rodgers et al., “Reduction of Membrane Fouling in the Ultrafiltration of Binary Protein Mixtures,” AIChE Journal, 1991, 37(10):1517-1528. [cited by applicant]
Roy et al., “Multivesicular liposomes containing bleomycin for subcutaneous administration,” Cancer Chemother. Pharmacol., 28(2):105-108, 1991. [cited by applicant]
Russack et al., “Quantitative Cerebrospinal Fluid Cytology in Patients Receiving Intracavitary Chemotherapy,” Ann. Neurol., 1993, 34(1):108-112. [cited by applicant]
Saberi et al., “Bubble Size and Velocity Measurement in Gas-Liquid Systems: Application of Fiber Optic Technique to Pilot Plant Scale,” Can. J. Chem. Eng., 1995, 73: 253-257. [cited by applicant]
Shakiba et al., “Evaluation of Retinal Toxicity and Liposome Encapsulation of the Anti-CMV drug 2′-nor-cyclic GMP,” Invest. Ophthalmol. Vis. Sci., 34(10):2903-2910, 1993. [cited by applicant]
Skuta et al., “Filtering Surgery in Owl Monkeys Treated with the Antimetabolite 5-Fluorouridine 5′ Monophosphate Entrapped in Multivesicular Liposomes,” Am. J. Ophtmalmol., 1987, 103(5):714-716. [cited by applicant]
Streiff et al., “Don't overlook static-mixer reactors,” Chem. Eng., Jun. 1994, pp. 76-82. [cited by applicant]
Szoka et al., “Comparative properties and methods of preparation of lipid vesicles (liposomes),” Ann. Rev. Biophys. Bioeng., 1980, 9:467-508. [cited by applicant]
Tanaka et al., “Crossflow Filtration of Baker's Yeast with Periodical Stopping of Permeation Flow and Bubbling,” Biotechnol. Bioeng., 1995, 47(3):401-404. [cited by applicant]
Thompson, G.A. Jr., The Regulation of Membrane Lipid Metabolism 2.sup.nd Ed., CRC Press: Boca Raton, pp. 1-20 (1992). [cited by applicant]
Tsuchiya et al., “Tortuosity of Bubble Rise Path in a Liquid-Solid Fluidized Bed: Effect of Particle Shape,” AIChE Journal, 1995, 41(6):1368-1374. [cited by applicant]
Turski et al., “Magnetic Resonance Imaging of Rabbit Brain after Intracarotid Injection of Large Multivesicular Liposomes Containing Paramagnetic Metals and DTPA,” Magn. Reson. Med., 7(2):184-196, 1998. [cited by applicant]
Watts et al., “Microencapsulation Using Emulsification/Solvent Evaporation: An Overview of Techniques and Applications,” Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7(3):235-259. [cited by applicant]
Zheng et al., “FDA Bioequivalence Standards, Chapter 11, Bioequivalence for Liposomal Drug Products,” AAPS Advances in the Pharmaceutical Sciences, vol. 13, 2014, 275-296. [cited by applicant]
International Search Report and Written Opinion dated Dec. 9, 2022 in International application No. PCT/US2022/046560. [cited by applicant]
Grit et al., 1993, Chemical stability of liposomes: implications for their physical stability, Chemistry and Physics of Lipids, 64:3-18. [cited by applicant]